Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib With or Without Bevacizumab in EGFR+ NSCLC and Brain Metastases
NCT02971501Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2018
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Arm I (osimertinib, bevacizumab) with Arm II (osimertinib) (2 arms). Primary endpoint: Progression Free Survival up to 63.7 months. Started Jun 2018; status: active, not recruiting.
02
Drugs
osimertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02971501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971501.